Nixon Peabody Trust Co. Sells 852 Shares of Danaher Corporation $DHR

Nixon Peabody Trust Co. cut its stake in shares of Danaher Corporation (NYSE:DHR) by 1.4% during the 2nd quarter, Holdings Channel.com reports. The firm owned 60,863 shares of the conglomerate’s stock after selling 852 shares during the quarter. Nixon Peabody Trust Co.’s holdings in Danaher were worth $12,023,000 as of its most recent filing with the SEC.

A number of other hedge funds have also modified their holdings of the company. Nuveen LLC bought a new position in Danaher in the 1st quarter worth $833,941,000. Generation Investment Management LLP increased its holdings in shares of Danaher by 56.2% in the 2nd quarter. Generation Investment Management LLP now owns 4,965,646 shares of the conglomerate’s stock worth $980,914,000 after buying an additional 1,787,522 shares during the last quarter. Invesco Ltd. lifted its holdings in shares of Danaher by 44.5% in the 1st quarter. Invesco Ltd. now owns 4,708,578 shares of the conglomerate’s stock valued at $965,259,000 after acquiring an additional 1,450,703 shares during the last quarter. Baird Financial Group Inc. lifted its holdings in shares of Danaher by 290.6% in the 1st quarter. Baird Financial Group Inc. now owns 1,441,706 shares of the conglomerate’s stock valued at $295,550,000 after acquiring an additional 1,072,617 shares during the last quarter. Finally, Parnassus Investments LLC grew its position in Danaher by 23.3% in the first quarter. Parnassus Investments LLC now owns 3,828,024 shares of the conglomerate’s stock worth $784,745,000 after acquiring an additional 722,636 shares in the last quarter. 79.05% of the stock is currently owned by institutional investors.

Danaher Stock Up 1.0%

NYSE:DHR opened at $221.50 on Friday. The company has a debt-to-equity ratio of 0.33, a current ratio of 1.52 and a quick ratio of 1.10. Danaher Corporation has a 1-year low of $171.00 and a 1-year high of $258.23. The company has a 50-day moving average of $205.21 and a 200 day moving average of $200.91. The firm has a market cap of $156.46 billion, a PE ratio of 45.67, a price-to-earnings-growth ratio of 3.28 and a beta of 0.81.

Danaher (NYSE:DHR) last posted its quarterly earnings results on Monday, October 20th. The conglomerate reported $1.89 EPS for the quarter, beating the consensus estimate of $1.72 by $0.17. Danaher had a net margin of 14.44% and a return on equity of 10.92%. The business had revenue of $6.05 billion during the quarter, compared to analyst estimates of $6 billion. During the same quarter in the previous year, the business posted $1.71 EPS. The company’s quarterly revenue was up 4.4% compared to the same quarter last year. As a group, research analysts anticipate that Danaher Corporation will post 7.63 EPS for the current fiscal year.

Danaher Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Friday, October 31st. Shareholders of record on Friday, September 26th were issued a dividend of $0.32 per share. The ex-dividend date was Friday, September 26th. This represents a $1.28 dividend on an annualized basis and a yield of 0.6%. Danaher’s dividend payout ratio is currently 26.39%.

Analyst Ratings Changes

A number of brokerages have issued reports on DHR. JPMorgan Chase & Co. upped their price objective on Danaher from $260.00 to $270.00 and gave the company an “overweight” rating in a research report on Wednesday, October 22nd. Guggenheim restated a “buy” rating and set a $250.00 price target on shares of Danaher in a report on Wednesday, July 23rd. Wells Fargo & Company restated a “positive” rating on shares of Danaher in a report on Thursday, October 23rd. Evercore ISI increased their price objective on shares of Danaher from $226.00 to $245.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 7th. Finally, Deutsche Bank Aktiengesellschaft boosted their target price on Danaher from $235.00 to $250.00 and gave the company a “buy” rating in a research report on Wednesday, October 22nd. Eighteen investment analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $243.39.

Insider Buying and Selling at Danaher

In related news, Director Teri List sold 2,778 shares of the firm’s stock in a transaction dated Friday, August 22nd. The stock was sold at an average price of $211.06, for a total transaction of $586,324.68. Following the sale, the director owned 20,751 shares of the company’s stock, valued at $4,379,706.06. This trade represents a 11.81% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, SVP Georgeann Couchara sold 5,174 shares of the business’s stock in a transaction dated Monday, November 10th. The stock was sold at an average price of $210.42, for a total transaction of $1,088,713.08. Following the completion of the transaction, the senior vice president owned 2,625 shares of the company’s stock, valued at $552,352.50. This represents a 66.34% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 29,728 shares of company stock valued at $6,448,990. 11.20% of the stock is currently owned by corporate insiders.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.